Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
14 search results for:

Bendamustine 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 21-08-2017 | Multiple myeloma | Article

    Lenalidomide in combination with bendamustine and prednisolone in relapsed/refractory multiple myeloma: results of a phase 2 clinical trial (OSHO-#077)

    The authors report the results of their multicenter phase 2 trial which evaluates the safety, tolerability and activity of lenalidomide in combination with bendamustine and prednisolone in patients with relapsed or refractory multiple myeloma. Beck J et al.  J Cancer Res Clin Oncol 2017. DOI:10.1007/s00432-017-2504-5

  2. 24-08-2018 | Chronic lymphocytic leukemia | News | Article

    Obinutuzumab plus venetoclax shows promise for chronic lymphocytic leukemia

    Obinutuzumab and venetoclax, preceded by bendamustine debulking for high tumor loads, shows high response rates without unexpected or cumulative toxicities in patients with chronic lymphocytic leukemia, a phase II trial suggests.

    Published in:
    Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30414-5 Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30442-X
  3. 03-04-2018 | Chronic lymphocytic leukemia | News | Article

    Venetoclax plus rituximab improves relapsed, refractory CLL outcomes

    No new safety signals were observed with either regimen, and tumor lysis syndrome of grade 3 or 4 occurred in six patients (3.1%) in the venetoclax group and two (1.1%) in the bendamustine group.

    Published in:
    N Engl J Med 2018; 378 : 1107–1120
  4. 06-09-2018 | Follicular lymphoma | News | Article

    Lenalidomide plus rituximab comparable to follicular lymphoma standard of care

    Participants could receive the investigator’s choice of one of three rituximab-based regimens (rituximab given alongside cyclophosphamide, vincristine, and prednisone either with or without doxorubicin or rituximab plus bendamustine), after which they received maintenance rituximab on the same schedule as the lenalidomide group.

    Published in:
    N Engl J Med 2018; 379 : 934–947
  5. 13-04-2017 | Lymphoma | Article

    Cancer-specific geriatric assessment and quality of life: important factors in caring for older patients with aggressive B-cell lymphoma

    Ribi K, Rondeau S, Hitz F et al. Support Care Cancer 2017. doi:10.1007/s00520-017-3698-4

  6. 23-11-2017 | FDA | News | Article
    approvalsWatch

    FDA announces approvals for sunitinib, obinutuzumab

    The anti-CD20 agent had previously been approved by the FDA in combination with bendamustine for the second-line treatment of follicular lymphoma patients who had experienced relapse after receiving a rituximab-containing regimen or been unresponsive to it.

  7. 14-03-2017 | Lymphoma | Case report | Article

    SLL and CLL

    Bendamustine In a randomized trial comparing bendamustine to chlorambucil among previously untreated CLL/SLL patients, overall response rate (ORR) and median progression-free survival (PFS) were significantly better on the bendamustine arm (67% and 22 months, respectively) than for those receiving chlorambucil (30% and 8 months, respectively), p <0.0001 for both [10].

    Author:
    Tanya Siddiqi, Steven T Rosen
  8. 29-12-2016 | Lymphoma | Article

    The landscape of new drugs in lymphoma

    Other ADCs are also being investigated in combination with chemotherapy regimens, such as R-CHOP and rituximab plus bendamustine.

    Author:
    Anas Younes, Stephen Ansell, Nathan Fowler, Wyndham Wilson, Sven de Vos, John Seymour, Ranjana Advani, Andres Forero, Frank Morschhauser, Marie Jose Kersten, Kensei Tobinai, Pier Luigi Zinzani, Emanuele Zucca, Jeremy Abramson, Julie Vose
  9. 14-10-2016 | Hematologic cancers | Article

    T-cell lymphomas, a challenging disease: types, treatments, and future

    Ma H & Abdul-Hay M. Int J Clin Oncol 2017; 22: 18–51. doi:10.1007/s10147-016-1045-2

  10. 04-01-2016 | Treatment | Article

    Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity

    PFS (26.3 vs 17.6 months; P <0.001) and 24-month OS rates (73.3% vs 65%; P =0.04) were significantly improved with carfilzomib. 54 Other combination therapies that include pegylated liposomal doxorubicin, bendamustine and melphalan with dexamethasone, IMiDs and PIs are listed in Table 4.

    Author:
    R F Cornell, A A Kassim
  11. 15-03-2016 | Treatment | Article

    The future of cancer treatment: immunomodulation, CARs and combination immunotherapy

    In a study carried out at MSKCC, in which nine patients were treated, the first three patients did not receive conditioning therapy, and the following six patients received cyclophosphamide or bendamustine conditioning 147, 148 .

    Author:
    Danny N. Khalil, Eric L. Smith, Renier J. Brentjens, Jedd D. Wolchok
  12. 03-11-2015 | Hematologic cancers | Article

    Novel immunotherapies in lymphoid malignancies

    A pilot study at UPenn, in 14 patients with relapsed and/or refractory CLL, demonstrated an overall response rate (ORR) of 57%, with three outcomes fully published and the remainder presented in abstracts. 45, 60, 61 Preconditioning chemotherapy varied and included fludarabine, pentostatin, cyclophosphamide, or bendamustine.

    Author:
    Connie Lee Batlevi, Eri Matsuki, Renier J. Brentjens, Anas Younes
  13. 07-02-2015 | Hematologic cancers | Book chapter | Article

    Prognosis and therapy of chronic lymphocytic leukemia and small lymphocytic lymphoma

    Sun and Wienster review key prognostic markers, current and emerging therapy, and the future outlook for the management of patients with chronic lymphocytic leukemia and small lymphocytic lymphoma. Sun C & Wiestner A. In:  Non-Hodgkin Lymphoma . Edited by Evens AM, Blum KA. Springer International Publishing, 2015. doi:10.1007/978-3-319-13150-4_6

  14. 04-07-2018 | FDA | News | Article
    approvalsWatch

    FDA expands indications for venetoclax, bevacizumab

    This decision is based on the phase III MURANO trial which showed significantly better progression-free survival (PFS) in patients with relapsed or refractory CLL who received venetoclax alongside rituximab than those given bendamustine plus rituximab. --- Bevacizumab, initially given alongside chemotherapy and then as a single agent, is now approved for women who have undergone resection of stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal cancer.

  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.